Abstract:Introduction: Pancreatic ductal adenocarcinoma (PDAC) is currently the 3rd leading cause of cancer-related deaths in North American with ~10% survival 5 years after diagnosis. A contributing factor to this low survival rate is chemotherapy resistance. Major risk factors for PDAC, including smoking and chronic pancreatitis, promote activation of the unfolded protein response (UPR). The UPR reduces protein load to alleviate stress, and cancer cells can utilize the UPR to promote cell survival. We previously showed loss of Activating Transcription Factor 3 (ATF3), a mediator of the UPR, restricted early events in PDAC progression. The goal of this study was to determine if ATF3 and the UPR promote resistance to chemotherapy in PDAC. We hypothesized that cancer cells activate the UPR and ATF3 to reduce cell stress and promote chemotherapeutic resistance. Methods: Murine-derived organoids (MDOs) were developed from pancreatic tissue expressing KRASG12D with (Ptf1acreERT/+KRASG12D/+) or without Atf3 (Atf3-/-Ptf1acreERT/+KRASG12D; referred to as APK) expression, and patient-derived organoids (PDOs) were examined for mediators of the UPR. Transcriptomic changes related to ATF3 loss was determined by RNA-sequencing of Ptf1acreERT/+KRASG12D/+ and APK organoids. UPR activation was examined by qRT-PRC in MDOs and PDOs with and without gemcitabine treatment, and related to organoid viability and phenotype. PDOs viability was examined following treatment with gemcitabine +/- UPR inhibitors. Results: RNA-seq analysis of Ptf1acreERT/+KRASG12D/+ and APK MDOs identified drug metabolism cytochrome P450, metabolism of xenobiotics by cytochrome P450, and platinum drug resistance as key pathways affected by the loss of ATF3 suggesting reduced UPR activation impacts drug metabolism in KRASG12D expressing cells. Ptf1acreERT/+KRASG12D/+ and APK MDOs showed a differential response in cell viability and UPR activation to gemcitabine treatment suggesting an importance of ATF3 in gemcitabine resistance. Consistent with this role, treatment of PDOs with gemcitabine resulted in UPR activation in a patient-specific fashion, particularly regarding increased expression of ATF3 and spliced XBP1. In lines showing enhanced UPR activation to gemcitabine, combinatorial treatment with UPR inhibitors showed increased cell death compared to gemcitabine alone. Conclusions: This study shows the UPR and ATF3 are rapidly activated in response to gemcitabine, but in a patient-specific fashion. These results suggest cancer cells activate the UPR to increase resistance to chemotherapies, and a subset of patients may benefit from combined gemcitabine treatment with UPR inhibitors. Since the tumor microenvironment is believed to be a major contributing factor to chemotherapy resistance, future experiments will include the tumor microenvironment interactions and UPR inhibition. Citation Format: Mickenzie B. Martin, Teresa Borello, Fatemeh Mousavi, Nelson Dusetti, Christopher L. Pin. Targeting the unfolded protein response enhances sensitivity to chemotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr B090.

Activating transcription factor 3-mediated chemo-intervention with cancer chemokines in a noncanonical pathway under endoplasmic reticulum stress

ATF4/NUPR1 Axis Promotes Cancer Cell Survival and Mediates Immunosuppression in Clear Cell Renal Cell Carcinoma

CK1 stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer

ER Stress-Related ATF6 Upregulates CIP2A and Contributes to Poor Prognosis of Colon Cancer

Endoplasmic Reticulum Stress Regulates Tumor Growth and Anti-Tumor Immunity: a Promising Opportunity for Cancer Immunotherapy

Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy

Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer

Overexpression of the Transcription Factor ATF3 with a Regulatory Molecular Signature Associates with the Pathogenic Development of Colorectal Cancer

Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling

A Novel ER Stress Mediator TMTC3 Promotes Squamous Cell Carcinoma Progression by Activating GRP78/PERK Signaling Pathway

ER Stress-Enhanced HMGA2 Plays an Important Role in Cr (Vi)-Induced Glycolysis and Inhibited Oxidative Phosphorylation by Targeting the Transcription of ATF4

Endoplasmic Reticulum-Golgi Intermediate Compartment Protein 3 Knockdown Suppresses Lung Cancer Through Endoplasmic Reticulum Stress-Induced Autophagy.

TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis

Activating transcription factor 3 is a new biomarker correlation with renal clear cell carcinoma progression

ER Stress and Cancer: the FOXO Forkhead Transcription Factor Link

Abstract B090: Targeting the unfolded protein response enhances sensitivity to chemotherapy

Role of ATF3 in Synergistic Cancer Cell Killing by a Combination of HDAC Inhibitors and Agonistic Anti-Dr5 Antibody Through ER Stress in Human Colon Cancer Cells

ATF3 Induction Following DNA Damage is Regulated by Distinct Signaling Pathways and Over-Expression of ATF3 Protein Suppresses Cells Growth

Activating Transcription Factor 3 Promotes Colon Cancer Metastasis

Integrated Regulation of Autophagy and Apoptosis by Eef2k Controls Cellular Fate and Modulates the Efficacy of Curcumin and Velcade Against Tumor Cells

Endoplasmic Reticulum Stress Induced Autophagy in Cancer and Its Potential Interactions with Apoptosis and Ferroptosis.